Sourcing High‑Purity Rare Isotopes for Radiopharmaceuticals Amid Global Shortages

High‑purity rare isotopes for radiopharmaceuticals can still be sourced despite worldwide shortages by diversifying suppliers, using alternative production routes, and implementing strict quality‑control protocols. Key actions include engaging multiple certified manufacturers, verifying ISO/REACH compliance, and maintaining a validated inventory management system.

How can I obtain high‑purity rare isotopes for radiopharmaceuticals when global supplies are constrained?

The first step is to map the current supply chain for the isotope of interest. For ^99mTc, the traditional supply relies on ^99Mo produced in a handful of reactors (e.g., NRU, HFR). Recent reactor outages have reduced global capacity to roughly 70 % of pre‑2020 levels. To mitigate this, consider:

• Generator‑based procurement – ^68Ge/^68Ga generators provide on‑site ^68Ga without the need for cyclotron access. Typical generator capacities range from 1.85 GBq to 5.55 GBq, with a shelf‑life of 6 months.
• Cyclotron production – Direct cyclotron production of ^99mTc via ^100Mo(p,2n) can supply up to 10 GBq per batch, but requires a high‑energy (≥ 19 MeV) cyclotron and validated target recovery.
• Alternative isotopes – When ^99mTc is unavailable, ^111In or ^123I can serve as functional substitutes for certain imaging protocols, albeit with different photon energies and half‑lives.

Engage with at least two ISO‑9001‑certified manufacturers. Molekula, for example, maintains a portfolio of GMP‑grade isotopes sourced from both European and North‑American facilities, allowing customers to switch suppliers without re‑qualifying the material.

What quality‑control measures are essential for rare isotopes used in clinical radiopharmacy?

Regulatory frameworks (e.g., USP <823>, EP 10.0) require a documented quality‑control (QC) programme for each isotope batch. Core QC tests include:

| Test | Typical Acceptance Criteria | |------|----------------------------| | Radionuclidic purity (γ‑spectrometry) | ≥ 99.9 % for ^99mTc, ≥ 95 % for ^225Ac | | Chemical purity (ICP‑MS) | ≤ 10 ppm metallic impurities | | Sterility (membrane filtration) | No growth after 14 days incubation | | Endotoxin (LAL) | ≤ 0.5 EU mL⁻¹ | | pH (pH‑meter) | 4.5–7.5 for most aqueous formulations |

All certificates of analysis (CoA) must reference the relevant pharmacopeial monograph and include the assay, half‑life, and decay data. For isotopes with short half‑lives, the time between QC release and patient administration should be recorded to ensure dose accuracy.

Which alternative production routes or suppliers can mitigate shortages of key isotopes?

• Accelerator‑driven production – Linear accelerators can generate ^99Mo via photon‑induced fission of ^238U, offering a non‑reactor pathway. Pilot plants in Canada and the Netherlands have demonstrated yields of 2–3 TBq per week.
• Re‑processing of spent targets – Facilities that recover ^68Ga from irradiated ^68Zn targets can increase overall availability by up to 30 % when recycling is implemented.
• Regional supplier networks – Establishing agreements with suppliers in the Asia‑Pacific region (e.g., Australian cyclotron centres) reduces dependence on European reactors. Shipping times for ^177Lu are typically 2–3 days under controlled temperature conditions.
• Molecule‑specific contracts – For high‑value isotopes such as ^225Ac, multi‑year contracts with dedicated production lines (e.g., Oak Ridge National Laboratory) provide price stability and guaranteed delivery volumes (often 10–20 kBq kg⁻¹ per batch).

When evaluating a new supplier, verify:

1. ISO 13485 or ISO 9001 certification.
2. Compliance with REACH and TSCA for transport and handling.
3. Availability of a full SDS and up‑to‑date CoA for each batch.

How should I manage inventory and regulatory compliance for scarce isotopes?

Effective inventory management balances the short half‑life of many isotopes with the need to avoid stock‑outs. Recommended practices:

• Just‑in‑time ordering – Align order dates with scheduled patient cohorts. For ^68Ga, a 48‑hour lead time is sufficient for most clinical sites.
• Cold‑stock of parent nuclides – Maintain a reserve of long‑lived parents (e.g., ^68Ge, ^225Ac) to generate daughter isotopes on‑site. A 5 GBq ^68Ge stock can support up to 30 patient doses per week.
• Automated tracking – Use a LIMS that records decay calculations, batch numbers, and expiry dates. Integration with the hospital’s electronic prescribing system reduces manual transcription errors.
• Regulatory documentation – Keep a master file containing all import licences, GMP certificates, and audit trails. For cross‑border shipments, ensure the carrier holds a valid IATA Dangerous Goods Declaration.

Regularly review the supplier performance metrics (on‑time delivery, QC pass rate) and update the risk register accordingly.

What trends are shaping the future availability of rare isotopes for radiopharmaceuticals?

1. Decentralised production – Compact cyclotrons (≤ 30 MeV) are being installed in regional hospitals, enabling on‑site synthesis of ^18F, ^68Ga, and ^64Cu. This reduces reliance on centralised reactors.
2. Isotope‑specific licensing – The FDA’s Emerging Technology Programme is streamlining IND submissions for novel isotopes such as ^225Ac, potentially expanding commercial supply.
3. Sustainable target materials – Enriched ^100Mo and ^68Zn are being recycled using ion‑exchange columns, lowering raw‑material costs by up to 40 %.
4. Digital twins of supply chains – AI‑driven models predict shortages weeks in advance, allowing procurement teams to pre‑emptively secure alternative sources.

Staying informed about these developments helps organisations adapt their sourcing strategies before shortages become critical.

Frequently asked questions

Q1: Can I use a lower‑purity isotope for pre‑clinical work? A: Yes, provided the impurity profile does not interfere with the assay. However, any transition to clinical use will require a GMP‑grade, high‑purity batch.

Q2: How long can a ^68Ge/^68Ga generator be stored before use? A: Generators retain usable activity for up to 12 months if stored at 2–8 °C and protected from light.

Q3: What documentation is needed for customs clearance of ^177Lu? A: A commercial invoice, a GMP certificate, the SDS, and a transport declaration complying with IATA regulations.

Q4: Is it advisable to stockpile ^99mTc directly? A: Direct stockpiling is impractical due to the 6‑hour half‑life. Instead, maintain a supply of ^99Mo generators and elute ^99mTc as needed.